EU drugs regulator says it won’t impose 50% efficacy threshold for Covid-19 vaccines after disappointing result in CureVac trial
CureVac announced data on the efficacy of its jab on Wednesday after it was tested in second- and third-phase trials involving 40,000 people across ten countries.
The company suggested variants of the virus may be behind the poor result.Also on rt.com Trial of Germany’s CureVac vaccine shows only 47% effect against Covid-19, falling short of great expectations
On Thursday, the EMA’s vaccine chief Marco Cavaleri said it was “a bit early to say” after being asked by a journalist about the CureVac results and the threat variants may pose to vaccine efficacy.
“We will need to collect all the final data from this clinical trial, and have a good analysis of the outcome throughout different regions, age groups and according to different variants,” he told an EMA briefing.
Asked specifically about a 50% efficacy minimum level for vaccines, he added that the EMA had “always felt it was difficult to define upfront a threshold.”
Think your friends would be interested? Share this story!